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Objective: To identify risk factors for cardiovascular disease in patients with Rheumatoid
Arthritis (RA).
Material and methods: A descriptive cross-sectional study with 71 patients with established
RA. The instruments used were: DAS-28, HAQ and SF-36, and the following parameters
were determined: the erythrocyte sedimentation rate, capillary blood glucose; total choles-
terol (TC) and its fractions, thyroid hormones, antinuclear antibodies (ANA), rheumatoid
factor (RF) and antibodies against citrullinated proteins (ACPAs). Patients were classiﬁed
into groups HAQ ≤ 1 (mild dysfunction) and HAQ > 1 (moderate and severe dysfunction) and,
according to the HAQ scores, in groups treated with corticosteroids (CS) and without CS.
Results: 9 patients were male and 62 female with mean age and duration of disease of 53.45
(±10.7) and 9.9 (±8.6), respectively. RF was positive in 52 (76%), ACPAs in 54 (76.1%) and ANA
in  12 (16.9%). Thirty-six patients (50.7%) had systemic hypertension, 9 (12.68%) diabetes
mellitus, 16 (22.5%) hypothyroidism, 33 (46.5%) dyslipidemia and 8 (11.27%) were smokers.
The  results of TC > 240 were found in 53.8% for group HAQ > 1 (26) and in 24.4% for group
HAQ ≤ 1 (45) (p = 0.020). These groups did not differ as to presence of comorbidities or drug
treatment. Triglyceride levels >200 for the group with CS (42.4%) versus without CS (18.42%)
were  signiﬁcant (p = 0.025).
Conclusion: An association of increased TC and triglycerides with results of HAQ ≤ 1 and
with  CS use was noted, reinforcing the importance of screening risk factors associated withcardiovascular disease in RA.
© 2015 Elsevier Editora Ltda. All rights reserved.
∗ Corresponding author.
E-mail: ramaojunior@ufgd.edu.br (R.S.d. Deus Junior).
ttp://dx.doi.org/10.1016/j.rbre.2015.07.012
255-5021/© 2015 Elsevier Editora Ltda. All rights reserved.
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Caracterizac¸ão de  pacientes  com  artrite  reumatoide  quanto  a  fatores  de
risco  para  doenc¸as vasculares  cardíacas  no  Mato  Grosso  do  Sul
Palavras-chave:
Artrite reumatoide
Autoanticorpos
Comorbidades
r  e  s  u  m  o
Objetivo: Caracterizar pacientes com Artrite Reumatoide (AR) quanto à presenc¸a de fatores
de  risco para doenc¸as cardiovasculares.
Material e métodos: Estudo transversal descritivo com 71 pacientes diagnosticados com
AR  deﬁnida. Foram utilizados os instrumentos: DAS-28, HAQ e SF-36 e determinados os
parâmetros: velocidade de hemossedimentac¸ão, glicemia capilar; colesterol total (CT) e suas
frac¸ões,  hormônios tiroidianos, anticorpos antinúcleo (ANA), fator reumatoide (FR) e anti-
corpos contra proteínas citrulinadas (ACPAs). Os pacientes foram classiﬁcados em grupos
HAQ ≤1 (disfunc¸ão leve) e HAQ >1 (disfunc¸ão moderada e grave) e, segundo os escores do
HAQ, em grupo tratado com corticosteroides (CE) e sem CE.
Resultados: Proporc¸ão de 9 homens para 62 mulheres com idade e tempo médio de doenc¸a
de  53,45 (± 10,7) e 9,9 (± 8,6), respectivamente. O FR foi positivo em 52 (76%), os ACPAs em
54  (76,1%) e ANA em 12 (16,9%). Trinta e seis pacientes (50,7%) apresentaram hipertensão
arterial sistêmica, 9 (12,68%) Diabetes mellitus, 16 (22,5%) hipotireoidismo, 33 (46,5%) dislipi-
demia e 8 (11,27%) tabagismo. O grupo HAQ >1 (26) apresentou resultados de CT >240 (53,8%)
e  o grupo com HAQ ≤1 (45) (24,4%) (p = 0,020). Os grupos não diferiram quanto à presenc¸a
de  comorbidades ou tratamento farmacológico. Os níveis de triglicérides >200 (42,4%) entre
os  grupos em uso de CE e sem uso (18,42%) foi signiﬁcativo (p = 0,025).
Conclusão: Houve associac¸ão do aumento CT e triglicerídeos com resultados de HAQ ≤1 e
com  uso de CE, reforc¸ando a importância do rastreamento de fatores de risco associados às
doenc¸as  cardiovasculares na AR.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.
surement were considered hypertensive. Later, the diagnosisIntroduction
Rheumatoid Arthritis (RA) is a chronic, inﬂammatory, autoim-
mune disease, with unknown etiology, associated with
progressive joint dysfunction, whose consequence for patients
is functional limitation for their daily and professional activi-
ties. Furthermore, RA can lead to systemic complications and
early mortality.1
The pharmacological research involving RA has changed
considerably, and the current treatment recommends the
introduction of an early and aggressive therapeutic action,
guided by disease activity indexes. However, what has been
observed is that some patients do not present effective results
to available treatments.2
In addition, higher severity and early mortality from car-
diovascular disease in these patients, when compared to the
healthy population,3 remains a challenge for physicians who
are monitoring these patients.
Current published literature advocates the identiﬁcation of
subgroups of patients with different prognosis and therapeu-
tic responses.4 Thus, this study aimed to characterize patients
diagnosed with RA in terms of risk factors for cardiovascular
disease, identifying possible markers that show those patients
with worse prognosis, treated or not treated with corticoste-
roids, such as: IgM class rheumatoid factor antibodies (RF),
antibodies against citrullinated proteins (ACPAs), and antin-
uclear antibodies (ANA); presence of comorbidities: systemic
hypertension (SH), diabetes mellitus (DM), hypo- or hyperthy-
roidism and dyslipidemias, and to correlate these markerswith clinical activity of disease, functional status and quality
of life.
Material  and  methods
This is a descriptive cross-sectional study that evaluated con-
secutive patients from July 2012 to February 2013, attended
at the Rheumatoid Arthritis Outpatient Clinic, Department
of Rheumatology, University Hospital (UH) of Universidade
Federal de Grande Dourados (UFGD). The study included
71 patients of both genders previously diagnosed with RA,
who met  the 1987 American College of Rheumatology crite-
ria for RA.5 Patients who agreed to participate in this study
signed an informed consent form. The project was approved
by the Research Ethics Committee of UFGD, protocol num-
ber 14136013.0.0000.5160. Patients were clinically assessed by
rheumatologists who calculated disease activity with the Dis-
ease Activity Score for 28 joints (DAS-28), using as laboratory
parameter the erythrocyte sedimentation rate.6
Clinical evaluation included the body mass index (BMI) that
was computed as weight divided by height squared. Individ-
uals were weighed barefoot wearing light clothes t, using a
scale and stadiometer (WELMY). Patients with a previous diag-
nosis and in use of antihypertensive medication, as well as
those with an elevated blood pressure at the time of mea-of hypertension was conﬁrmed during follow-up, according to
Brazilian Society of Hypertension guidelines.7 We  considered
as diabetic those patients being treated for the disease and
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Table 1 – Demographics and clinical data of patients
with RA.
Demographics and clinical data
Gender, n (%) 62♂–9♀
Age, (±SD) 53.4 (±10.8)
Disease duration, (±SD) 9.9 (±8.4)
Disease onset, (±SD) 43.5 (±11.5)
Smoking, n (%) 18 (23.35)
BMI, X (±SD) 27.63 (±4.61)
Hypertension, n (%) 36 (50.07)
Diabetes, n (%) 9  (12.68)
Hypothyroidism, n (%) 16  (22.57)
RF positive, n (%) 54  (76.1)
ACPA positive, n (%) 52 (73.2)
ANA positive, n (%) 12 (16.9)
DAS-28, (±SD) 0.84 (1.53)
HAQ, (±SD) 1.36 (0.90)
SF-36, (±SD) 53.45 (10.75)
TC > 240, n (%) 24 (33.80)
LDL > 160, n (%) 15 (21.12)
Triglycerides > 200, n (%) 21 (29.57)
HDL > 35, n (%) 8 (11.26)
TC/HDL, n (%) 31 (43.66)
TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-r e v b r a s r e u m a t o l
lso those showing changes in blood glucose at the diagno-
is, later conﬁrmed according to Brazilian Society of Diabetes
uidelines.8
In tests for plasma lipids, we considered as dyslipidemic
hose patients in use of medication for this condition and/or
ith dietary measures recommended for the disease, as well
s those who had their results for dyslipidemia conﬁrmed dur-
ng follow-up in at least one more  laboratory analysis.
Functional status was assessed using the Health Assess-
ent Questionnaire (HAQ) (simpliﬁed) validated and trans-
ated into Portuguese.9 The parameters were correlated with
AQ results associated with use or not use of corticosteroids;
nd patients were classiﬁed according to the score in groups
AQ ≤ 1 (mild dysfunction) and HAQ > 1 (moderate and severe
ysfunction), considering the reduced number of patients
ith severe dysfunction in this study.
Quality of life was analyzed by the instrument The Short
orm (36) Health Survey (SF-36) validated and translated into
ortuguese.10
We  collected 15 mL  of each patient’s blood on clinical eval-
ation day, for performing an erythrocyte sedimentation rate
ESR) test by Westergreen method (mm/1st hour) in the same
ay of collection.
For determining blood glucose, a drop of blood was
eposited in the blood glucose test strip meter (G-TECH model
ree1).
To test anti-nuclear antibodies (ANA), HEp-2 cells were
sed (EUROIMMUN, Germany) and analyzed by indirect
mmunoﬂuorescence according to the protocol suggested by
he manufacturer.
The enzyme-linked immunosorbent assay (ELISA) was
sed to identify the presence of anti-cyclic citrullinated pep-
ide (Anti-CCP-3) (INOVA), rheumatoid factor (RF) (ORGENTEC),
nd anti-mutated citrullinated vimentin (Anti-MCV) (ORGEN-
EC). Triiodothyronine (T3 and free T3) and thyroxine (T4 and
ree T4) hormones were measured by electrochemilumines-
ence with the use of a Cobas E411 (ROCHE LTD.) analyzer and
sing kits supplied by the manufacturer.
Total cholesterol and its fractions were performed in a
obas Integra E400 plus (ROCHE Ltd.) analyzer, also using kits
upplied by the manufacturer.
The presence of rheumatoid factor was evaluated by latex
gglutination, but also by Waaler–Rose test, for IgM isotypes,
ccording to manufacturer’s protocols.
Statistical analysis was performed with SPSS (Statistical
ackage for Social Sciences) version 20.0. To characterize the
ample, we  used descriptive statistics; and data are presented
s mean (X) ± standard deviation (SD) for quantitative vari-
bles, and absolute (f) and relative (%) frequencies for qualita-
ive variables. Statistical inference was used for the remaining
nalyzes. To compare continuous variables with normal distri-
ution, Student’s t-test was performed; otherwise Mann Whit-
ey test was used. Categorical variables were compared using
isher exact test. The signiﬁcance level was set at p < 0.05.esults
eventy-one patients of both genders, previously diagnosed
ith RA, were evaluated; of these, 62 (87.32%) were femaledensity lipoprotein.
and 9 (12.68%) were male, an approximate ratio of 7:1. The
mean age of patients was 53.4 (±10.8) years. The mean dis-
ease duration was 9.9 (±8.4) years, with a median of 7 years,
ranging from 1 to 42 years. The mean for disease onset was
43.5 (±11.5) years, with a median of 43 years, ranging from 17
to 73 years old (more demographics data in Table 1).
Ten (14.08%) of 71 patients were smokers, while eight
(11.27%) of 71 were former smokers, totaling 18/71 (25.35%)
patients that had had contact with tobacco. Sera from 15 of
these patients were positive for anti-citrullinated protein anti-
bodies (ACPAs). Of the three negative sera for these antibodies,
one came from a former smoker and two from current smok-
ers.
The mean BMI was 27.63 ± 4.61. About 1/3 of patients
(30.98%) had an adequate weight/height relation in the period
of data collection. The others were distributed into overweight
(28/71, 40%) or obese (21/71, 29.58%) category.
As for systemic hypertension (SH), 35/71 (49.29%) patients
had this disease diagnosed and were using antihypertensive
medication. During the screening tests, 32 (44.44%) patients
presented with elevated blood pressure. Of these 32 patients,
two had no previous diagnosis of hypertension. SH was con-
ﬁrmed in another patient during the implementation period
of the study, totaling 36/71 (50.7%) patients with a diagnosis of
hypertension.
As for glycemic proﬁle, 7/71 (9.86%) patients had a previ-
ous diagnosis of diabetes mellitus (DM). However, 22 (30.98%)
patients exhibited elevated fasting glucose in screening tests
performed on the day of blood collection. Of these, only two
had a previous diagnosis of DM. Later, three of the other 20
patients had a conﬁrmed diagnosis of DM,  totaling 12.68%
(9/71) patients with this disease. Of these 22 patients, ﬁve
were corticosteroid users, including 2 patients with a previous
diagnosis of DM.
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Table 2 – Medications used in patients with RA (n = 71).
Medications n (%)
Non-steroidal anti-inﬂammatory drugs
(NSAIDs)
27  (38.03)
Corticosteroids 33 (46.47)
Chloroquine/sulfasalazine 29 (40.84)
MTX 32 (45.07)
Leﬂunomide 27 (38.03)
MTX + Leﬂunomide 1 (1.40)
Anti-TNF 34 (47.89)
MTX/Leﬂunomide + anti-TNF 32 (45.07)
MTX/Leﬂunomide + anti-TNF or
leﬂunomide + chloroquine/sulfasalazine
10  (14.84)
Table 3 – Association of clinical and laboratory
parameters with HAQ.
HAQ ≤ 1 (45) HAQ > 1 (26) p
Age, (±SD) 52.91 ± 10.62 54.38 ± 11.31 0.47
Disease duration, (±SD) 9.76 ± 7.32 10.31 ± 10.29 0.64
Disease onset, (±SD) 43.16 ± 11.43 44.08 ± 11.72 0.73
Smoking (f) 13 (28.88) 5 (19.23) 0.37
Body mass index, (±SD) 27.22 ± 4.42 28.11 ± 5.84 0.39
Systemic hypertension (f) 22 (48.88) 14 (53.84) 0.63
Diabetes mellitus (f) 6 (13.33) 3 (11.53) 1.00
Hypothyroidism (f) 13  (28.88) 4 (15.38) 0.084
Corticosteroids (f) 17  (37.77) 16 (61.53) 0.083
Metotrexate (f) 21 (29.57) 11 (24.44) 0.91
Leﬂunomide (f) 17 (23.94) 10 (22.22) 0.84
Anti-TNF (f) 19 (42.22) 14 (53.84) 0.46
Total cholesterol > 240 (f) 11 (24.44) 14 (53.84) 0.020
HDL < 35 (f) 7 (15.55) 1 (3.84) 0.24
LDL > 160 (f) 6 (13.33) 9 (34.61) 0.067
Triglycerides > 200 (f) 10 (22.22) 10 (38.46) 0.17
DAS-28 (±SD) 4.48 ± 1.28 5.13 ± 1.42 0.024
SF-36 P (±SD) 39.2 ± 12.92 27.12 ± 12.71 <0.0001
SF-36 M (±SD) 48.69 ± 9.35 34.19 ± 10.50 <0.0001
SF-36 T (±SD) 42.55 ± 8.13 29.35 ± 7.37 <0.0001
anti-TNF, anti-tumor necrosis factor; HDL, high density lipoprotein;
LDL, low density lipoprotein; DAS-28, diseases activity score in 28
joints; SF-36 P, short-form health survey (physical domain); SF-36
higher prevalence of risk factors.MTX, metotrexate; Anti-TNF, anti-tumor necrosis factor.
As for thyroid disease, 13/71 (18.30%) were on thyroid hor-
mone replacement therapy, while 2/71 (2.81%) were being
treated for hyperthyroidism. However, according to results
of laboratory tests, four patients showed serological changes
consistent with hypothyroidism and only one of these patients
had been already in treatment, totaling 16/71 (22.53%) patients
with hypothyroidism.
Seropositivity was characterized as follows: 37/71 (52.1%)
patients were positive for rheumatoid factor (RF) by ELISA, and
9/71 (12.67%) were positive only for RF. Using the latex method,
positivity was of only 28/71 (39.4%) and 17 of these patients
were also positive by Waaler–Rose method. The positivity for
RF was of 54/71 (76.1%), and those patients who had their
results conﬁrmed by the same method, or who were positive
by two different methods, were regarded as positive cases.
As to anti-cyclic Citrullinated Peptide (Anti-CCP) by Elisa,
36/71 (50.70%) patients were positive, and 3/71 (4.22%) were
positive only for anti-CCP. As to anti-mutated citrullinated
vimentin (anti-MCV) by Elisa, 48/71 (67.60%) patients were pos-
itive, with 11/71 (15.49%) positive only for anti-MCV. Thus,
52/71 (73.2%) were positive for anti-citrullinated protein anti-
bodies (ACPAs).
Positivity for RF and ACPA was diagnosed in 34/71 (47.9%)
of sera.
Serological analysis for antinuclear antibodies (ANA)
resulted in 12/71 (16.90%) positive results, and no patient was
positive exclusively for these antibodies.
Regarding the positivity association for autoantibodies,
7/71 (9.9%) patients were positive for all analyzed antibodies.
The same number was negative for RF and ACPAs.
As for prescription drugs for treatment of RA, Table 2
shows that 27/71 (38.03%) and 33/71 (46.47%) patients had
nonsteroidal anti-inﬂammatory drugs and corticosteroids
prescribed, respectively. Leﬂunomide was taken by 27/71
(38.03%) and methotrexate (MTX) by 32/71 (45.07%); and in
1/71 (1.40%) both medications were used. 34/71 (47.89) patients
had prescription for biologicals (anti-TNF blockers), and 32/34
(94.11%) were associated with leﬂunomide or MTX.
Regarding dyslipidemia, 6/71 (8.45%) of patients had been
previously diagnosed, and four were taking medication (two
treated with simvastatin, one with atorvastatin and one with
benzaﬁbrate) and two other were in dietary therapy. Only
1/6 (16.7%) had normal lipid levels. However, according to
screening tests, 33/71 (46.5%) had some type of dyslipidemiaM, short-form health survey (mental domain); SF-36 T, short-form
health survey (total score).
(Table 3), conﬁrmed in at least one previous test, or subse-
quently during follow-up.
As for disease activity through DAS-28, 4/71 (5.63%) patients
were found in a state of remission, 5/71 (7.04%) with mild dis-
ease activity, 29/71 (40.84%) with moderate disease activity and
33/71 (46.47%) patients with severe disease activity.
SF-36 was the questionnaire used to evaluate the quality of
life of patients with RA. The results indicated that the mean
values were 34.68 ± 13.05 for Physical Health Dimension and
43.33 ± 15.28 for Mental Health Dimension, with a mean total
SF-36 score of 36.68 ± 13.35.
Regarding physical disability of patients (HAQ), the results
were 45/71 (63.38%) with a mild level of disability, 21/71
(29.57%) for a moderate condition and 5/71 (7.04%) for a severe
condition. Statistical signiﬁcance was noted for total choles-
terol (p = 0.020), DAS-28 (p = 0.024) and for physical domain
(p < 0.0001), mental domain (p < 0.0001) and total (p < 0, 0001)
SF-36, as shown in Table 3. Of these patients, 37.78% (17/54)
were taking CS in HAQ > 1 group and 61.54% (16/26) in HAQ ≤ 1
group (p = 0.084).
Table 4 shows the results of the analysis of cholesterol lev-
els and its fractions in patients not taking CS in relation to
HAQ > 1.
Statistically signiﬁcant differences were found in TC > 240
(p = 0.019), HAQ ≤ 1 (5/28 = 21.42%), HAQ > 1 (6/10 = 60%) and
SF-36 (p = 0.013) variables. The results of these biochemical
parameters for patients in treatment with CS were not pre-
sented, because the treatment with CS is associated with aWhen the results of lipid levels for CS users versus not users
were compared, we did not ﬁnd statistical differences in total
cholesterol (p = 0.20) or SF-36 (p = 0.094); but for triglyceride
r e v b r a s r e u m a t o l . 2 0 1
Table 4 – Analysis of cholesterol level and its fractions,
disease activity index and quality of life in patients
without use of CS in relation to HAQ > 1.
HAQ ≤ 1 (28) HAQ > 1 (10) p
Total cholesterol > 240 (f) 5 (17.86) 6 (60) 0.019
HDL < 35 (f) 5 (17.86) 0 (0) 0.96
LDL > 160 (f) 3 (10.71) 4 (40) 0.60
Triglycerides > 200 (f) 5 (17.86) 2 (20) 0.61
DAS-28 (±SD) 4.5 ± 1.48 5.29 ± 0.89 0.089
SF-36 (±SD) 43.39 ± 12.10 31.30 ± 13.81 0.013
HDL, high-density lipoprotein; LDL, low-density lipoprotein; DAS-
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survey.
evels a statistical difference (p = 0.025) was noted, according
o Table 5.
The higher prevalence of cardiovascular diseases, par-
icularly coronary artery disease, is well established in RA.
egarding CS and dyslipidemias, admittedly CS treatment
ncrease total cholesterol, LDL and triglyceride levels and
educe HDL; thus, in this study these variables were not ana-
yzed in relation to the results of HAQ ≤ 1.0.
iscussion
heumatoid arthritis is a disease that affects both genders in
 proportion of 3–4 women for every man.11 In this study the
ender ratio in our sample was 7:1, corroborating the results
ound by Boechat et al.,12 who studied 350 non-indigenous
atients in the state of Amazonas, and also emphasizes ﬁnd-
ngs of European and American studies, who obtained a ratio
f about 7:1.13–15
Presence of antibodies such as RF and anti-CCP are impor-
ant prognostic markers for response to treatment. In this
tudy it was observed that 12/71 (16.90%) patients were pos-
tive for ANA, a result that differs from a Japanese study,
hose result was 39/104 (37.5%) (p = 0.038)16 and from a Euro-
ean study that showed positivity for ANA in 16/36 (44%)
atients (p = 0.0045).17 Research of anti-MCV antibodies was
ositive in 48/71 (66.66%) patients–a result similar to the Nor-
egian study by Besada et al., who found positive cases in
Table 5 – Comparison of lipid levels in patients with or
without use of CS.
With CS (n = 33) Without CS
(n = 38)
p
Total cholesterol > 240 12 (36.36) 12 (31.58) 0.20
HDL < 35 3 (9.09) 5 (13.16) 0.44
LDL > 160 7 (21.21) 8 (21.05) 0.61
Triglycerides > 200 14 (42.42) 7 (18.42) 0.025
HAQ 0.98 ± 0.72 0.73 ± 0.61 0.12
DAS-28 4.69 ± 1.14 4.74 ± 1.18 0.85
SF-36 34.85 ± 12.9 40.21 ± 13.41 0.094
HDL, high-density lipoprotein; LDL, low-density lipoprotein; HAQ,
health assessment questionnaire; DAS-28, disease activity score in
28 joints; SF-36, short-form health survey. 5;5 5(6):493–500 497
57/75 (76%),18 and to the European study by Sghiri et al.,
whose result was 74.1% of positivity for anti-MCV in 170 sera
from RA patients.19 As for anti-CCP, our results were sim-
ilar to those found in studies in other Brazilian areas, for
instance, Teixeira et al. and Silva et al., with results of 24/38
(63.15%) and 68/100 (68%), respectively.20,21 Our results were
higher than those of a Colombian study, which showed 53/165
(33.1%) of reactive sera for anti-CCP (p = 0.0084).22 The results
of RF positivity have been controversial in Brazilian studies,
ranging from 49.3 to 91%.20,23,24 In a Korean study the inci-
dence of reactive samples was 209/302 (69.2%),25 a signiﬁcantly
higher positivity than that found in this study: 37/71 (52.11%)
(p = 0.0077).
RA is a disease associated with lower life expectancy, when
compared to the general population.26 This fact is explained by
the increase in prevalence as well as by a greater progression
of cardiovascular diseases in these patients.27 Genetic factors
and classic risk factors associated with inﬂammation for these
diseases contribute to an increase and greater severity of car-
diovascular diseases in RA.28
Current and former smoking are considered one of the
few risk factors associated with RA with conﬁrmation in epi-
demiological studies.29,30 This risk factor was identiﬁed in
1/4 of the patients in this study, which indicates a higher
proportion of smokers than that found by Mikuls et al.,31
who identiﬁed smoking in 52/605 (8.52%) patients with RA
(p < 0.0001).
As for BMI, results of a German study with 551 patients,
which identiﬁed values of 26.7 ± 5.1, corroborate our results
of 27.6 ± 4.94. Our results were similar to those of Myasoe-
dova et al.,32 who reported that 3/4 of patients with RA have
BMI  above the normal index.33 In addition, the proportion
of overweight and obese patients, as determined from BMI
according to the criteria for the general population, may be
underestimated, because it has been shown that, for a given
amount of body fat, patients with RA have 2 pounds/m2 less
than normal controls. Therefore, BMI for these patients should
be deﬁned as 23 and 28 kg/m2 for overweight and obesity,
respectively.34
In relation to systemic hypertension, the results showed
that 36/71 (50.70%) of RA patients had this disease, reinforcing
the ﬁndings of Cunha et al., who reported systemic hyperten-
sion in 95/228 (41.66%) patients with RA.35 Our results were
similar to those found by Ferraz-Amaro et al., showing sys-
temic hypertension in 36/101 (35.74%) of RA patients.36
As for thyroid disease, 16/71 (22.53%) of patients had
hypothyroidism and 2/71 (2.82%) hyperthyroidism, results
similar to those of Chan et al., who found 12/69 (17.4%) cases of
hypothyroidism and 4/69 (5.8%) of hyperthyroidism in patients
with RA.37
In a study by Park et al., diabetes was diagnosed in 27/302
(8.9%) patients,25 while in the study by Giuseppe et al., the dis-
ease was diagnosed in 4/132 (3%) of patients.38 In the present
study, the diagnosis was conﬁrmed in 9/71 (12.67%) patients,
a ﬁnding similar to that in the ﬁrst study, and signiﬁcantly
higher than in the second study (p = 0.0035), respectively.
The analyzed sample showed a higher prevalence of dia-
betic patients, 9/71 (12.67%), when compared to the study
conducted in the state of Amazonas, Brazil, 4/142 (3%)
(p = 0.0030).12
 o l . 2498  r e v b r a s r e u m a t
As for quality of life, the results indicate that few patients
achieved remission or mild disease activity, 4 and 5%,
respectively, although only 5% of patients had HAQ associated
with severe functional status.
The decreased quality of life in patients with less physi-
cal dysfunction was assessed by SF-36, admittedly a reliable
and valid tool and able to measure important clinical fea-
tures in RA patients. Its use has also been advocated during
clinical follow-up of these patients, as SF-36 evaluates dif-
ferent areas, not just the physical domain.39 In this study,
besides the physical domain, the mental domain was also
decreased in patients with high HAQ score. Mental health
is an important topic, because depression is associated with
poor treatment adherence and with increased morbidity and
mortality.40
The presence of dyslipidemias in 36/71 (50.70%) patients
showed a signiﬁcantly higher frequency than that found by
Park et al., where 58/302 (19.2%) of a Korean population with
RA were dyslipidemic patients.25
Lipid disorders are one of the most important risk fac-
tors for cardiovascular disease and studies have shown that
they are more  prevalent in RA patients than in the gen-
eral population.41 In untreated patients with RA, Park et al.
demonstrated that these patients present reduction in HDL
cholesterol levels and that this change is related to C-reactive
protein levels.42 In untreated patients, total cholesterol and
LDL reductions also occur.41 Some authors also described that
a decrease in inﬂammation coincides with an increase in
serum levels of lipids.13,43,44
Despite the limitations of this study, of a cross-sectional
nature, we found that total cholesterol levels are associated
with higher physical dysfunction. The use of corticosteroids
was more  prevalent among patients with increased levels of
triglycerides, but not among patients with high total choles-
terol levels. Thus, Ferraz-Amaro et al. demonstrated decrease
in the activity of cholesterol ester transfer protein (CETP) in RA
patients who  are undergoing treatment with CS, but showed
no difference in lipid levels in patients who were undergoing
treatment with versus without corticosteroids.36 The function
of this protein is complex and its relation to cardiovascular
risk is not well understood.
The use of DMARDs can also induce increases in
total cholesterol and in HDL and triglyceride fractions,
especially methotrexate, leading to changes called “normal-
ization” according to Saiki.45 Regarding anti-TNF blockers,
the published literature have shown increased rates of total
cholesterol and also of all its fractions; however, Choy and
Sattar reported that a meta-analysis is not possible, because
the studies differ on the type of intervention and follow-up
time.41
In this study, it was found that patients in RA treatment
had lipid levels considered as a risk factor for cardiovascular
disease.46 However, there was no correlation between these
levels and disease activity, as assessed by DAS-28, similar to
Navarro Millán et al.’s results,13 who also found no difference
between patients treated with methotrexate monotherapy ver-
sus those treated with a combination therapy with anti-TNF
blockers. However, the authors reported a signiﬁcant increase
in total cholesterol and in all its fractions in those patients
assessed. 0 1 5;5 5(6):493–500
The patients in this study had been referred from the Basic
Health Unit. It was observed that, before the treatment by
a specialist, little was added to the diagnosis of systemic
hypertension, diabetes and thyroid disease. These ﬁndings
corroborate data from Desai et al., who showed that general
practitioners were the professionals who treated risk factors
for cardiovascular disease, not rheumatologists.47 However,
general practitioners identiﬁed more  risk factors in the general
population and in diabetics than in the RA population.
In this sense, the diagnosis of dyslipidemia has been
underestimated, probably because RA association with cardio-
vascular risk and lipid abnormalities are not yet established
in the literature and, therefore, this feature was not dissem-
inated among general practitioners.13 The recent published
data shows evidence that dyslipidemias are present years
before the onset of clinical symptoms of RA.48 Park et al.
reported that polymorphisms associated with LDL  cholesterol
(rs688 and rs4420638) are also related to RA susceptibility,
severity and progression.49
Therefore we emphasize that the screening of several
risk factors for cardiovascular disease indicates the need for
pharmacological treatment and lifestyle changes, in order to
achieve a better control of RA, so that these patients may
improve their quality of life and decrease the risk for systemic
complications.
Conclusion
From this study it was concluded that: (1) notwithstanding
the therapeutic arsenal available to these patients, only a few
have achieved remission or a state of mild disease activity;
on the other hand, 5% were evolving to severe dysfunction.
(2) A high prevalence of underdiagnosed dyslipidemia was
observed in these patients. (3) Treatment with corticoste-
roids is associated with a higher prevalence of patients with
hypertriglyceridemia. (4) Higher levels of total cholesterol are
associated with more  physical disability. (5) The quality of life
is reduced in patients with major physical disability; however,
this factor is not associated with the use, or not, of corticoste-
roids. (6) Follow-up of patients with RA is a complex task, due
to the high risk for developing cardiovascular disease, thus
requiring control not only of the disease activity, but also of
traditional risk factors.
For future studies, it is suggested the establishment of more
homogeneous groups to determine the inﬂuence of the dis-
ease and drug treatments used with respect to the presence
of risk factors for cardiovascular disease in patients with RA.
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